The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives

References

• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386:983–994.
   PubMed Web of Science ®Google Scholar
• Kleyn CE, Talbot PS, Mehta NN, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol. 2020;100:1–8. adv00020. .
   Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–1799.
   PubMed Web of Science ®Google Scholar
• Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127:1339–1345.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–120.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol. 2016;28:163–171.
   PubMed Web of Science ®Google Scholar
• Mercurio L, Morelli M, Scarponi C, et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018;9:1104.
   PubMed Web of Science ®Google Scholar
• Boutet M-A, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: a Comprehensive Review of Their Therapeutic Potential. Int J Mol Sci. 2019;20:20. .
   Web of Science ®Google Scholar
• Hernandez-Santana YE, Giannoudaki E, Leon G, et al. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol. 2019;49:1306–1320. .
   PubMed Web of Science ®Google Scholar
• Quirk S, Agrawal DK. Immunobiology of Interleukin-37: mechanism of action and clinical perspectives. Expert Rev Clin Immunol. 2014;10:1703–1709.
   PubMed Web of Science ®Google Scholar
• Zhou L, Todorovic V. Interleukin-36: structure, Signaling and Function. Adv Exp Med Biol. 2020 Feb 6. DOI:10.1007/5584_2020_488.
   Google Scholar
• Zhou T, Damsky W, Weizman O-E, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609–614.
   PubMed Web of Science ®Google Scholar
• Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286:42594–42602.
   PubMed Web of Science ®Google Scholar
• Mora J, Weigert A. IL-1 family cytokines in cancer immunity - a matter of life and death. Biol Chem. 2016;397:1125–1134. .
   PubMed Web of Science ®Google Scholar
• Uppala R, Tsoi LC, Harms PW, et al. “Autoinflammatory psoriasis”-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18:307-317.
   PubMed Web of Science ®Google Scholar
• Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem. 1995;270:27758–27765.
   PubMed Web of Science ®Google Scholar
• Rider P, Carmi Y, Voronov E, et al. Interleukin-1α. Semin Immunol. 2013;25:430–438.
   PubMed Web of Science ®Google Scholar
• Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA. 2004;101:2434–2439.
   PubMed Web of Science ®Google Scholar
• Cohen I, Rider P, Carmi Y, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA. 2010;107:2574–2579.
   PubMed Web of Science ®Google Scholar
• Miwa K, Asano M, Horai R, et al. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998;4:1287–1292.
   PubMed Web of Science ®Google Scholar
• Renne J, Schäfer V, Werfel T, et al. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol. 2010;162:1198–1205.
   PubMed Web of Science ®Google Scholar
• Mee JB, Cork MJ, Di Giovine FS, et al. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006;33:72–78.
   PubMed Web of Science ®Google Scholar
• Uribe-Herranz M, Lian L-H, Hooper KM, et al. IL-1R1 signaling facilitates Munro’s microabscess formation in psoriasiform imiquimod-induced skin inflammation. J Invest Dermatol. 2013;133:1541–1549.
   PubMed Web of Science ®Google Scholar
• Cai Y, Xue F, Quan C, et al. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. J Invest Dermatol. 2019;139:146–156.
   PubMed Web of Science ®Google Scholar
• Verma D, Fekri SZ, Sigurdardottir G, et al. Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation. J Invest Dermatol. 2020. DOI:10.1016/j.jid.2020.07.012.
   PubMedGoogle Scholar
• Tang L, Zhou F. Inflammasomes in common immune-related skin diseases. Front Immunol. 2020;11:882.
   PubMed Web of Science ®Google Scholar
• Niu X-L, Huang Y, Gao Y-L, et al. Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in a mouse model of imiquimod-induced psoriasis. Chin Med J (Engl). 2019;132:690–698.
   PubMed Web of Science ®Google Scholar
• hyun LJ, Cho DH, Park HJ. IL-18 and cutaneous inflammatory diseases. Int J Mol Sci. 2015;16:29357–29369.
   PubMed Web of Science ®Google Scholar
• Shimoura N, Nagai H, Fujiwara S, et al. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch Dermatol Res. 2017;309:315–321.
   PubMed Web of Science ®Google Scholar
• Balato A, Raimondo A, Balato N, et al. Interleukin-33: increasing role in dermatological conditions. Arch Dermatol Res. 2016;308:287–296.
   PubMed Web of Science ®Google Scholar
• Cannavò SP, Bertino L, Di Salvo E, et al. Possible roles of IL-33 in the innate-adaptive immune crosstalk of psoriasis pathogenesis. Mediators Inflammation. 2019;2019:7158014.
   PubMed Web of Science ®Google Scholar
• Lefrançais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA. 2012;109:1673–1678.
   PubMed Web of Science ®Google Scholar
• Lefrançais E, Duval A, Mirey E, et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci USA. 2014;111:15502–15507.
   PubMed Web of Science ®Google Scholar
• Smithgall MD, Comeau MR, Yoon B-RP, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–1030.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu Y, Gong Y, et al. Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response. Immunology. 2020;160:382–392.
   PubMed Web of Science ®Google Scholar
• Mitsui A, Tada Y, Takahashi T, et al. Serum IL-33 levels are increased in patients with psoriasis. Clin Exp Dermatol. 2016;41:183–189.
   PubMed Web of Science ®Google Scholar
• Duan Y, Dong Y, Hu H, et al. IL-33 contributes to disease severity in Psoriasis-like models of mouse. Cytokine. 2019;119:159–167.
   PubMed Web of Science ®Google Scholar
• Athari SK, Poirier E, Biton J, et al. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis Res Ther. 2016;18:143.
   PubMed Web of Science ®Google Scholar
• Hueber AJ, Alves-Filho JC, Asquith DL, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol. 2011;41:2229–2237.
   PubMed Web of Science ®Google Scholar
• Suttle -M-M, Enoksson M, Zoltowska A, et al. Experimentally induced psoriatic lesions associate with rapid but transient decrease in interleukin-33 immunostaining in epidermis. Acta Derm Venereol. 2015;95:536–541.
   PubMed Web of Science ®Google Scholar
• Madonna S, Girolomoni G, Dinarello CA, et al. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int J Mol Sci. 2019;20:20.
   Web of Science ®Google Scholar
• Martin U, Scholler J, Gurgel J, et al. Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J Immunol. 2009;183:4021–4030.
   PubMed Web of Science ®Google Scholar
• Kovach MA, Singer BH, Newstead MW, et al. IL-36γ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. J Leukocyte Biol. 2016;100:413–421.
   PubMed Web of Science ®Google Scholar
• Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines. Cell Rep. 2016;14:708–722.
   PubMed Web of Science ®Google Scholar
• Macleod T, Doble R, McGonagle D, et al. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist. Sci Rep. 2016;6:24880.
   PubMed Web of Science ®Google Scholar
• Clancy DM, Henry CM, Sullivan GP, et al. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. Febs J. 2017;284:1712–1725.
   PubMed Web of Science ®Google Scholar
• Clancy DM, Sullivan GP, Moran HBT, et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 Cytokine activity but poor effectors of microbial killing. Cell Rep. 2018;22:2937–2950.
   PubMed Web of Science ®Google Scholar
• Guo J, Tu J, Hu Y, et al. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis. Drug Des Devel Ther. 2019;13:581–588.
   PubMed Web of Science ®Google Scholar
• Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell. 2011;44:265–278.
   PubMed Web of Science ®Google Scholar
• Sehat M, Talaei R, Dadgostar E, et al. Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with Psoriasis Vulgaris. Iran J Allergy Asthma Immunol. 2018;17:179–187.
   PubMed Web of Science ®Google Scholar
• Bal E, Lim AC, Shen M, et al. Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome. Exp Dermatol. 2019;28:1114–1117.
   PubMed Web of Science ®Google Scholar
• Vigne S, Palmer G, Lamacchia C, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118:5813–5823.
   PubMed Web of Science ®Google Scholar
• Li N, Yamasaki K, Saito R, et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol. 2014;193:5140–5148.
   PubMed Web of Science ®Google Scholar
• Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukocyte Biol. 2015;97:645–652.
   PubMed Web of Science ®Google Scholar
• Carrier Y, Ma H-L, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131:2428–2437.
   PubMed Web of Science ®Google Scholar
• Milora KA, Fu H, Dubaz O, et al. Unprocessed Interleukin-36α Regulates Psoriasis-Like skin inflammation in cooperation with interleukin-1. J Invest Dermatol. 2015;135:2992–3000.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Fearnley GW, Berekmeri A, et al. IL-36γ is a strong inducer of IL-23 in Psoriatic cells and activates angiogenesis. Front Immunol. 2018;9:200.
   PubMed Web of Science ®Google Scholar
• Catapano M, Vergnano M, Romano M, et al. IL-36 promotes systemic IFN-I responses in severe forms of Psoriasis. J Invest Dermatol. 2020;140(816–826):e3. .
   PubMedGoogle Scholar
• Bachelez H, Choon S-E, Marrakchi S, et al. Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular Psoriasis. N Engl J Med. 2019;380:981–983.
   PubMed Web of Science ®Google Scholar
• Irina Khanskaya JP, Marino MH, Savall T, et al. (2018) A phase 1 study of ANB019, an anti-IL-36 receptor monoclonal antibody, in healthy volunteers. [cited 2020 Dec 14]. Available from https://www2.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf.
   Google Scholar
• Boutet M-A, Nerviani A, Lliso-Ribera G, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford). 2020;59:828–838.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Catapano M, Di Meglio P, et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med. 2017;9:9.
   Web of Science ®Google Scholar
• Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122:3965–3976.
   PubMed Web of Science ®Google Scholar
• Su Z, Paulsboe S, Wetter J, et al. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol. 2019;28:113–120.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wen X, Hao D, et al. The role of IL-37 in skin and connective tissue diseases. Biomed Pharmacother. 2020;122:109705.
   PubMed Web of Science ®Google Scholar
• Li B, Tsoi LC, Swindell WR, et al. Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol. 2014;134:1828–1838.
   PubMed Web of Science ®Google Scholar
• Keermann M, Kõks S, Reimann E, et al. Expression of IL-36 family cytokines and IL-37 but not IL-38 is altered in psoriatic skin. J Dermatol Sci. 2015;80:150–152.
   PubMed Web of Science ®Google Scholar
• Teng X, Hu Z, Wei X, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol. 2014;192:1815–1823.
   PubMed Web of Science ®Google Scholar
• Li J, Liu L, Rui W, et al. New Interleukins in Psoriasis and Psoriatic arthritis patients: the possible roles of Interleukin-33 to Interleukin-38 in disease activities and bone erosions. Dermatology. 2017;233:37–46.
   PubMed Web of Science ®Google Scholar
• Russell SE, Stefanska AM, Kubica M, et al. Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by γδ T cells. J Immunol. 2013;191:3337–3346.
   PubMed Web of Science ®Google Scholar
• Han Y, Mora J, Huard A, et al. IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells. Cell Rep. 2019;27(835–846):e5.
   Google Scholar
• Palomo J, Troccaz S, Talabot-Ayer D, et al. The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. PLoS One. 2018;13:e0194667.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426–2437.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–628.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432–437.
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021–1026.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–1369.
   PubMed Web of Science ®Google Scholar
• Zhu T, Jin H, Shu D, et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur J Dermatol. 2018;28:217–224.
   PubMed Web of Science ®Google Scholar
• Hussain S, Berki DM, Choon S-E, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(1067–1070):e9. .
   Google Scholar
• Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178:740–748.
   PubMed Web of Science ®Google Scholar
• Akiyama M. Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2019;143:809–810.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133:2514–2521.
   PubMed Web of Science ®Google Scholar
• Blonska M, Lin XNF. κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011;21:55–70.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Cao L, Roberson EDO, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90:796–808.
   PubMed Web of Science ®Google Scholar
• Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis (PPP) in the Chinese Han population. Eur J Dermatol. 2019;29:99–100.
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44:1341–1348.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136:2251–2259.
   PubMed Web of Science ®Google Scholar
• Han J-W, Wang Y, Alateng C, et al. Tumor necrosis factor-alpha induced protein 3 interacting protein 1 gene polymorphisms and pustular Psoriasis in Chinese Han population. Chin Med J (Engl). 2016;129:1519–1524.
   PubMed Web of Science ®Google Scholar
• Frey S, Sticht H, Wilsmann-Theis D, et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular Psoriasis. J Invest Dermatol. 2020;140(1451–1455):e13. .
   PubMedGoogle Scholar
• McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133–144.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Takeichi T, McGrath JA, et al. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140:1545–1547.
   PubMed Web of Science ®Google Scholar
• Akiyama M, De Vita V, Sugiura K. Editorial: autoinflammatory Keratinization Disease (AiKD). Front Immunol. 2020;11:1753.
   PubMed Web of Science ®Google Scholar
• Liang Y, Xing X, Beamer MA, et al. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J Allergy Clin Immunol. 2017;139:1217–1227.
   PubMed Web of Science ®Google Scholar
• Pustular psoriasis elucidating underlying mechanism (PLUM) protocol. [cited 2020 Dec 14]. Accessed from http://apricot-trial.com/wp-content/uploads/2017/07/PLUM-Protocol_V1.1_03042017.pdf.
   Google Scholar
• Tauber M, Viguier M, Alimova E, et al. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br J Dermatol. 2014;171:646–649.
   PubMed Web of Science ®Google Scholar
• Wang W-M, Jin H-Z. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19:969–980.
   PubMed Web of Science ®Google Scholar
• Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol. 2012;148:301–304.
   PubMedGoogle Scholar
• Gottlieb A, Natsis NE, Kerdel F, et al. A phase ii open-label study of bermekimab in patients with Hidradenitis Suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(1538–1545):e2. .
   Google Scholar
• Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 Targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138:795–801.
   PubMed Web of Science ®Google Scholar
• Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017;176:212–215.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Kivelevitch D, Campa M, et al. Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab. Clin Exp Dermatol. 2016;41:324–326.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173:239–241.
   PubMed Web of Science ®Google Scholar
• Højen JF, Kristensen MLV, McKee AS, et al. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019;20:1138–1149.
   PubMed Web of Science ®Google Scholar
• Ågerstam H, Hansen N, von Palffy S, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128:2683–2693.
   PubMed Web of Science ®Google Scholar
• Zheng P, Zhang Y, Zhang B, et al. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer. Biomed Pharmacother. 2018;107:1064–1073.
   PubMed Web of Science ®Google Scholar
• Klementiev B, Li S, Korshunova I, et al. Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation. 2014;11:27.
   PubMed Web of Science ®Google Scholar
• Todorović V, Su Z, Putman CB, et al. Small Molecule IL-36γ Antagonist as a novel therapeutic approach for plaque Psoriasis. Sci Rep. 2019;9:9089.
   PubMed Web of Science ®Google Scholar
• Chen W-Y, Tsai T-H, Yang J-L, et al. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases. Cell Physiol Biochem. 2018;49:349–358.
   PubMedGoogle Scholar